Delcath Systems Inc (DCTH)

[Rapture2020]

I still believe we'll close green. The interim safety analysis report due out any time. Based on the 10Q discussions I think it's going to play out nicely.

The following sums up my position on DCTH. I've bought my fill and now I am holding for the FDA. The report will be out any day now:

Couple this with the fact that first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period and the acceleration is something that the more bullish operators out there might be inclined to get a bit excited about.

What’s of more interest to us, however, is the company’s comments on its lead development program. We noted in our coverage last week that any positive update on this program could seriously shift sentiment and we got what we were looking for. To add a bit of background, this program, a phase 3 clinical trial investigating Melphalan/HDS in hepatic dominant ocular melanoma, has basically been plodding along for the past twelve months as a sort of ongoing afterthought, with the capital constraints and a reverse split risk-taking center stage across the period.

With the reverse split in the rearview, however, and the capital constraints (somewhat) lifted, focus can now shift to the phase 3 program.

Management said it expects to ramp up enrollment over the coming months and – even more interesting – expects to put out an interim safety update before the end of this year. If we see a clean bill of health on the safety side of things, the stock is likely going to spike. If we get any indication of efficacy at the same time, it’s going to run.

https://insiderfinancial.com/delcath-systems-inc-otcmktsdcthd-just-ran-90-on-a-short-squeeze-we-predicted/173736/